¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Lucio leprosy phenomenon"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • crowding phenomenon
    ¹ÐÁýÇö»ó
  • cytopathogenic phenomenon
    ¼¼Æ÷º¯¼ºÇö»ó
  • centralization phenomenon
    Áß½ÉÈ­Çö»ó
  • duplication phenomenon
    º¹Á¦Çö»ó
  • delay phenomenon
    Áö¿¬Çö»ó
  • dawn phenomenon
    »õº®Çö»ó, ¿©¸íÇö»ó
  • discontinuity phenomenon
    ºÒ¿¬¼ÓÇö»ó
  • dissociative phenomenon
    ÇØ¸®Çö»ó
  • doll¡¯s head phenomenon
    ÀÎÇü¸Ó¸®Çö»ó
  • entoptic phenomenon
    ³»½ÃÇö»ó
  • entry phenomenon
    ÁøÀÔÇö»ó
  • entry slice phenomenon
    ÁøÀÔÀýÆíÇö»ó
  • escape phenomenon
    ÀÌÅ»Çö»ó
  • gap phenomenon
    °£±ØÇö»ó, Æ´Çö»ó
  • iceberg phenomenon
    ºù»êÇö»ó
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • critical phenomenon
    ÀÓ°èÇö»ó
  • crowding phenomenon
    ¹ÐÁýÇö»ó
  • cytopathogenic phenomenon
    ¼¼Æ÷º¯¼ºÇö»ó
  • delay phenomenon
    Áö¿¬Çö»ó
  • discontinuity phenomenon
    ºÒ¿¬¼ÓÇö»ó
  • dissociative phenomenon
    ÇØ¸®Çö»ó
  • doll¡¯s head phenomenon
    ÀÎÇü¸Ó¸®Çö»ó
  • down phenomenon
    »õº®Çö»ó, ¿©¸íÇö»ó
  • duplication phenomenon
    º¹Á¦Çö»ó
  • entoptic phenomenon
    ³»½ÃÇö»ó
  • entry phenomenon
    ÁøÀÔÇö»ó
  • entry slice phenomenon
    ÁøÀÔÀýÆíÇö»ó
  • escape phenomenon
    ÀÌÅ»Çö»ó
  • iceberg phenomenon
    ºù»êÇö»ó
  • identification phenomenon
    µ¿ÀϽÃÇö»ó
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Gunns pupillary phenomenon
    °Ç¾¾µ¿°øÇö»ó
  • Hirsts phenomenon
    Ç㽺Ʈ Çö»ó
  • Jack-in-the-box phenomenon
    µ¹¿¬½ÃÇö»ó
  • Kanagawa hemolysis phenomenon
    Ä«³ª°¡¿Í ¿ëÇ÷Çö»ó (º´¿ø¼º ºñºê¸®¿ÀÀÇ)
  • Kochs phenomenon
    ÄÚÈ£Çö»ó
  • Koebner phenomenon
    Äêºê³Ê Çö»ó
  • LE cell phenomenon
    LE¼¼Æ÷Çö»ó.
  • Lusts phenomenon
    ·¯½ºÆ® Çö»ó.
  • Mizuos phenomenon
    ¹ÌÁî¿ÀÇö»ó
  • Pel-Ebstein phenomenon
    Æç-¿¦½´Å¸ÀÎ Çö»ó
  • Pfeiffers phenomenon
    ÆÄÀÌÆÛ ¿ë±ÕÇö»ó (ÄÝ·¹¶ó±ÕÀÇ)
  • Pulfrich phenomenon
    Ç®ÇÁ¸®È÷Çö»ó
  • Raynaud s phenomenon
    ·¹À̳ëÇö»ó.
  • Raynauds phenomenon
    ·¹À̳ëµå Çö»ó
  • Riddoch phenomenon
    ¸®µµÅ©Çö»ó
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • leprosy of the larynx
    Èĵγªº´
  • leprosy,leonine facies
    »çÀÚ¾ó±¼
  • leprosy,lepromatous
    ³ªÁ¾¸ð¾ç(ÑÛðþÙ¼åÆ)
  • leprosy,tuberculoid
    °áÇÙ¸ð¾ç(Ì¿ú·Ù¼åÆ)
  • leprosy<³ª> lepra
    ³ª, ³ªº´(ÑÛÜ»).
  • leprosy<³ª> lepra
    ³ª, ³ªº´(ÑÛÜ»).
  • leprosy<³ª> lepra
    ³ªº´
  • macular leprosy
    ¹Ý»ó³ª(¡­ )
  • major tuberculoid leprosy
    ´ë°áÇپ糪(ÓÞÌ¿ ú·åÆÑÛ).
  • multibacillary leprosy
    ´Ù±Õ³ª
  • mutilating leprosy ³ª lepra mutilans
    Àý´Ü ³ª(ôîÓ¨ÑÛ)
  • neural leprosy
    ½Å°æ³ª.
  • neural leprosy
    ½Å°æ³ª(¡­³ª)
  • neural leprosy
    ½Å°æ³ª
  • nodular leprosy =tubercular l.
    °áÀý³ª(Ì¿ï½ ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
VF   1) Ventricular Fibrillation
    ? Tx of Ventricular Fibrillation ...
B-G Bordet-Gengou [agar, bacillus, phenomenon]
CREST calcinosis, Raynaud phenomenon, esophageal involvement, sclerodactyly, and telangiectasia [syndrome]...
CRST calcinosis, Raynaud phenomenon, sclerodactyly, telangiectasia [syndrome]; corrected sinus recovery t...
PRP physiologic rest position; pityriasis rubra pilaris; platelet-rich plasma; polyribosyl ribitol phosp...
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • central pain phenomenon
    ÁßÃß¼º µ¿Åë Çö»ó
  • Chiristensen phenomenon
    Å©¸®½ºÅÙ¼¾ Çö»ó
    ÇϾÇÀÇ Àü¹æ¿îµ¿ ½Ã ´ëÇÕÇÏ´Â ±³ÇÕ¸é »çÀÌ¿¡ »ý±â´Â °£°Ý.
  • Christensen's phenomenon
    Å©¸®½ºÅÙ¼¾ Çö»ó
  • Class Switching phenomenon
    ºÐ·ù Àüȯ Çö»ó
    ÇϳªÀÇ B ¼¼Æ÷°¡ ±×¿¡ »óÀÀÇÒ ¼ö Àִ ƯÀÌ Ç׿ø¿¡ Á¢ÇÏ¿´À» ¶§ isoty
  • dawn phenomenon
    »õº® Çö»ó
    Á¦ 1Çü ´ç´¢º´ ȯÀÚÀÇ 75%¿¡¼­, ±×¸®°í ´Ù¼öÀÇ Á¦ 2Çü ´ç´¢º´ ȯÀÚ ¹× Á¤»óÀο¡¼­µµ ÀϾ´Ù. À̰ÍÀº ¿ÀÀü 5-8½Ã »çÀÌ¿¡ Àν¶¸°¿¡ ´ëÇÑ Á¶Á÷ÀÇ °¨¼ö¼ºÀÌ °¨¼ÒÇÏ¿© ÀϾ´Ù. ÃÖ±ÙÀÇ Áõ°Å´Â ÀÌ Çö»óÀÌ ¼ö¸é Áß¿¡ ¼ºÀå È£¸£¸ó ºÐºñÀÇ Áõ°¡¿¡ ÀÇÇÏ¿© À¯¹ßµÇ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. »õº® Çö»óÀÌ ´Üµ¶À» ¹ß»ýÇϸé À̸¥ ¾ÆÄ§¿¡ °æµµÀÇ °íÇ÷´çÁõÀÌ ¿À³ª ¼Ò¸ð±â È¿°ú³ª °¨Åð Çö»óÀÌ µ¿¹ÝµÇ¸é °íÇ÷´çÁõÀº ½ÉÇØÁø´Ù.
  • dolls head phenomenon
    ÀÎÇü ¸Ó¸® Çö»ó, ÀÎÇü µÎ Çö»ó
  • flare phenomenon
    Àå°³ Çö»ó
  • Fowler phenomenon
    º¸Ãæ Çö»ó
  • iceberg phenomenon
    ºù»ê Çö»ó
  • jaw winking phenomenon
    ÅÎ-À®Å© Çö»ó
  • light absorption phenomenon
    ºû Èí¼ö Çö»ó
  • metallic phenomenon
    ±Ý¼Ó¼º Çö»ó
  • mucus extravasation phenomenon
    Á¡¾× À¯Ãâ Çö»ó
  • orbicularis phenomenon
    À±±Ù Çö»ó
  • phenomenon
    Çö»ó
    1. ¾î¶² ¡Èijª °´°üÀûÀÎ Áõ»ó. 2. ¾î¶² ÁÖ¸ñÇÒ¸¸ÇÑ »ç°Ç ¶Ç´Â »ç½Ç.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
dry leprosy A form of leprosy chiefly affecting the nerves, marked by hyperesthesia succeeded by anaesthesia, and by paralysis, ulceration, and various trophic disturbances, terminating in gangrene and mutilation.
Synonym: Danielssen's disease, Danielssen-Boeck disease, dry leprosy, trophoneurotic leprosy.
(05 Mar 2000)
indeterminate leprosy A transitory form of leprosy in which the immunologic status is not yet formed, and the histologic and clinical features are not yet characteristic of any of the major types of leprosy.
(05 Mar 2000)
trophoneurotic leprosy A form of leprosy chiefly affecting the nerves, marked by hyperesthesia succeeded by anaesthesia, and by paralysis, ulceration, and various trophic disturbances, terminating in gangrene and mutilation.
Synonym: Danielssen's disease, Danielssen-Boeck disease, dry leprosy, trophoneurotic leprosy.
(05 Mar 2000)
tuberculoid leprosy A benign, stable, and resistant form of the disease in which the lepromin reaction is strongly positive and in which the lesions are erythematous, insensitive, infiltrated plaques with clear-cut edges.
Synonym: nodular leprosy, smooth leprosy.
(05 Mar 2000)
lazarine leprosy An acute form occurring in pure diffuse lepromatous leprosy presenting irregularly shaped, intensely erythematous, tender plaques, especially of the legs, with tendency to ulceration and scarring.
Synonym: lazarine leprosy, Lucio's leprosy phenomenon.
(05 Mar 2000)
lepromatous leprosy A form of leprosy in which nodular cutaneous lesions are infiltrated, have ill-defined borders, and are bacteriologically positive; the lepromin test is negative, i.e., the immunologic mechanism of the patient is not responsive to the Mycobacterium leprae infection.
(05 Mar 2000)
leprosy <infectious disease> Caused by Mycobacterium leprae, an obligate intracellular parasite that survives lysosomal enzyme attack by possessing a waxy coat.
Leprosy is a chronic disease associated with depressed cellular (but not humoral) immunity, the bacterium requires a lower temperature than 37­C and thrives particularly in peripheral Schwann cells and macrophages.
Only humans and the nine banded armadillo are susceptible.
(18 Nov 1997)
leprosy bacillus A species of gram-positive, aerobic bacteria that causes leprosy in man. Its organisms are generally arranged in clumps, rounded masses, or in groups of bacilli side by side.
(12 Dec 1998)
leprosy, borderline A form of leprosy in which there are clinical manifestations of both principal types (lepromatous and tuberculoid). The disease may shift toward one of these two polar or principal forms.
(12 Dec 1998)
leprosy, lepromatous A chronic communicable infection which is a principal or polar form of leprosy. This disorder is caused by mycobacterium leprae and produces diffuse granulomatous skin lesions in the form of nodules, macules, or papules. The peripheral nerves are involved symmetrically and neural sequelae occur in the advanced stage.
(12 Dec 1998)
leprosy test <investigation> A test for leprosy where an extract of infected tissue (antigen) is injected under the skin to determine if you have a current or recent leprosy infection.
Normally, little or no skin reaction should result from the injection. A positive skin reaction indicates a leprosy infection.
(27 Sep 1997)
leprosy, tuberculoid A principal or polar form of leprosy in which the skin lesions are few and are sharply demarcated. Peripheral nerve involvement is pronounced and may be severe. Unlike lepromatous leprosy (leprosy, lepromatous), the lepromin test is positive. Tuberculoid leprosy is rarely a source of infection to others.
(12 Dec 1998)
adhesion phenomenon A phenomenon manifested by the adherence of antigen-antibody-complement complex to "indicator cells" (microorganisms, platelets, leukocytes, or erythrocytes), the reaction being sensitive and specific for the antigen and antibody in the complex.
Synonym: erythrocyte adherence phenomenon, immune adherence phenomenon, red cell adherence phenomenon.
(05 Mar 2000)
AFORMED phenomenon As induced pulsus alternans progresses, a state in which alternating heart depolarisations fail to eject any blood, thus allowing longer diastolic filling; the subsequent beat is then able to produce a significant ejection; at high rates the cardiac minute volume and blood pressure may appear normal.
Origin: Alternating, failure of response, mechanical, to electrical depolarisation
(05 Mar 2000)
all-or-nothing phenomenon <physiology> Refers to the phenomenon where the strength of a nerve impulse is not dependent on the strength of the stimulus. Instead, there is a threshold level of stimulus strength that must be reached before the nerve will fire an impulse (at full capacity). Below the threshold, the nerve will not fire at all.
<cardiology> It also refers to the same phenomenon observed in the heart muscle, which will either contract fully or not at all.
<psychology> In studies of behaviour, it refers to the same phenomenon where a behavioural stimulus will either produce a complete response or no response at all. Also called all-or-nothing principle, all-or-none law, all-or-none responsiveness, etc.
(15 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á